Unexpected hematological tolerance to high activity 186Re HEDP therapy for skeletal metastases in prostate carcinoma.

被引：0
|
作者：
McCready, VR
O'Sullivan, J
Norman, A
Dearnaley, DP
Treleaven, JG
Binnie, D
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Canc Res Inst, Sutton, Surrey, England
来源：
JOURNAL OF NUCLEAR MEDICINE | 2001年 / 42卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1300
引用
收藏
页码：313P / 313P
页数：1
相关论文
共 20 条
  • [1] Prediction of response of skeletal metastases from cancer of the prostate to high activity 186Re HEDP therapy.
    McCready, VR
    O'Sullivan, J
    Dearnaley, D
    Cook, G
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 316P - 316P
  • [2] [186Re]-HEDP in the palliation of painful bone metastases from cancers other than prostate and breast
    Minutoli, F.
    Herberg, A.
    Spadaro, P.
    Pecorella, G. Restifo
    Baldari, S.
    Arico, D.
    Altavilla, G.
    Baldari, S.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 50 (04): : 355 - 362
  • [3] Comparison of PSA measurements and scintigraphy in patients with skeletal metastases from carcinoma of the prostate treated with high activities of Re 186 HEDP.
    McCready, VR
    O'Sullivan, JM
    Dearnaley, DP
    Treleaven, J
    Cook, G
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 412P - 413P
  • [4] PBSC Transplantation in patients receiving ablative doses of 186Re HEDP for skeletal secondaries from prostate cancer
    McCready, R
    Treleaven, J
    Al Deen, A
    Dearnaley, D
    Powles, R
    BONE MARROW TRANSPLANTATION, 1998, 21 : S227 - S227
  • [5] The optimum method to determine the maximum tolerated activity for high activity Re186HEDP therapy with peripheral blood stem cell support for skeletal metastases from prostate cancer
    McCready, VR
    O'Sullivan, J
    Norman, A
    Treleaven, J
    Dearnaley, D
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S480 - S481
  • [6] High activity therapy for bone metastases from CA prostate using Re-186 HEDP and peripheral blood stem cell support
    McCready, VR
    David, D
    Trelevan, J
    Al-Deen, A
    RADIOLOGY, 1998, 209P : 438 - 438
  • [7] Effect of high dose Rhenium 186 HEDP with stem cell support on skeletal metastases in prostate cancer
    Al-Deen, A
    McCready, VR
    Dearnaley, DP
    Treleaven, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S344 - S344
  • [8] Quantitative analysis of bone scans to determine if the dose to individual metastases from high activity Re186HEDP therapy depends upon the number of metastases
    McCready, VR
    O'Sullivan, J
    Dearnaley, D
    Treleaven, J
    RADIOLOGY, 2001, 221 : 344 - 344
  • [9] Phase 2 Study of a High Dose of Re-186-HEDP for Bone Pain Palliation in Patients with Widespread Skeletal Metastases
    Pirayesh, Elahe
    Amoui, Mahasti
    Mirzaee, Hamid Reza
    Tabei, Faraj
    Rakhsha, Afshin
    Kalantari, Bagher Aziz
    Shafiei, Babak
    Assadi, Majid
    Asli, Isa Neshandar
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2013, 41 (03) : 192 - 196
  • [10] The potential use of 99mTc-MDP bone scans to plan high-activity 186Re-HEDP targeted therapy of bony metastases from prostate cancer
    Binnie, D
    Divoli, A
    McCready, VR
    Dearnaley, D
    Flux, G
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2005, 20 (02) : 189 - 194
12